New at WaveTec

Article

Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures.

Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures.

“The board appreciates Tom Berryman’s leadership and great contribution to the company's achievements, as well as his role in recruiting Tom Frinzi to the company. We are enormously pleased to welcome Tom to WaveTec,”said Charles Warden, of Versant Ventures a board member and investor in WaveTec. “Tom is a seasoned and dynamic leader who brings a wealth of proven commercial experience within the ophthalmic space. ”

Frinzi who began his career at Johnson & Johnson, is a 30 year veteran of the ophthalmic and medical device industries. Most recently, he served as Vice President of Global Commercial Operations at Bausch+Lomb Surgical where he was responsible for worldwide revenue of approximately $500 million generated via their cataract and vitreo‐retinal product portfolio.

“What attracted me to WaveTec is the potential to change the landscape of cataract surgery,” said Mr Frinzi. “What cornea topography was to refractive surgery, ORange can be to cataract surgery. The Premium Channel has raised expectations and WaveTec is uniquely positioned to help surgeons optimize their outcomes and ultimately improve the overall patient experience. That's exciting.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.